Prostate cancer screening: waiting for Godot.
作者信息
Iscoe N A
出版信息
CMAJ. 1998 Dec 1;159(11):1375-7.
Abstract
摘要
相似文献
1
Prostate cancer screening: waiting for Godot.前列腺癌筛查：等待戈多。
CMAJ. 1998 Dec 1;159(11):1375-7.
2
Screening for prostate cancer: estimating the magnitude of overdetection.前列腺癌筛查：评估过度诊断的程度。
CMAJ. 1998 Dec 1;159(11):1368-72.
3
Prostate specific antigen and screening for early prostate cancer.前列腺特异性抗原与早期前列腺癌筛查
N Z Med J. 2001 Apr 13;114(1129):150.
4
Prostate cancer screening: is it possible to explain diametrically opposed views?
N Z Med J. 2005 Feb 11;118(1209):U1289.
5
PSA screening: correlating noise with noise?前列腺特异性抗原筛查：将噪声与噪声关联起来？
CMAJ. 2002 Aug 20;167(4):340; author reply 340.
6
Re: Is a screening interval of every 4 years for prostate cancer acceptable?关于：前列腺癌每4年进行一次筛查的间隔时间是否可以接受？
J Natl Cancer Inst. 2008 Feb 6;100(3):222; author reply 223-4. doi: 10.1093/jnci/djm293. Epub 2008 Jan 29.
7
Research questions concerning prostate cancer screening.关于前列腺癌筛查的研究问题。
Cancer Causes Control. 1997 Jul;8(4):668-71. doi: 10.1023/a:1018410817024.
8
Screening for prostate cancer: recommendations and rationale.前列腺癌筛查：建议与依据。
Am J Nurs. 2003 Mar;103(3):107-10; discussion 111.
9
Interpreting the Quebec prostate cancer study.解读魁北克前列腺癌研究。
CMAJ. 2002 Aug 20;167(4):340.
10
New cancer screening guidelines say less is more.新的癌症筛查指南表明少即是多。
ONS Connect. 2009 Apr;24(4):19.
引用本文的文献
本文引用的文献
1
Pattern of changes over time in myocardial blood flow and microvascular dilator capacity in patients with normally functioning cardiac allografts.心脏移植功能正常患者心肌血流和微血管扩张能力随时间的变化模式。
Am J Cardiol. 1998 Dec 1;82(11):1377-81. doi: 10.1016/s0002-9149(98)00645-6.
2
Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.前列腺癌发病率与患者死亡率：筛查及早期检测的影响
Cancer. 1997 Nov 1;80(9):1857-63. doi: 10.1002/(sici)1097-0142(19971101)80:9<1857::aid-cncr26>3.0.co;2-3.
3
Should we screen for prostate cancer?我们应该筛查前列腺癌吗？
BMJ. 1997 Apr 5;314(7086):989-90. doi: 10.1136/bmj.314.7086.989.
4
Population-based study of long-term survival in patients with clinically localised prostate cancer.基于人群的临床局限性前列腺癌患者长期生存情况研究。
Lancet. 1997 Mar 29;349(9056):906-10. doi: 10.1016/S0140-6736(96)09380-4.
5
Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.前列腺癌的早期检测。第二部分：评估风险、益处和成本。美国医师学会。
Ann Intern Med. 1997 Mar 15;126(6):468-79. doi: 10.7326/0003-4819-126-6-199703150-00010.
6
Prostate cancer: are we screening and treating too much?前列腺癌：我们的筛查和治疗是否过度？
Ann Intern Med. 1997 Mar 15;126(6):465-7. doi: 10.7326/0003-4819-126-6-199703150-00009.
7
Longitudinal screening for prostate cancer with prostate-specific antigen.使用前列腺特异性抗原对前列腺癌进行纵向筛查。
JAMA. 1996;276(16):1309-15.
8
Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors.1960年至1988年瑞典前列腺癌生存率趋势：非致命性肿瘤诊断增加的证据。
J Natl Cancer Inst. 1996 Sep 4;88(17):1216-21. doi: 10.1093/jnci/88.17.1216.
9
Results of conservative management of clinically localized prostate cancer.
N Engl J Med. 1994 Jan 27;330(4):242-8. doi: 10.1056/NEJM199401273300403.
10
Screening for prostate cancer.前列腺癌筛查
JAMA. 1995 Apr 19;273(15):1173-4; author reply 1175-6. doi: 10.1001/jama.1995.03520390031018.
Zotero 插件